Johnson & Johnson CFO Says Guidance Hike Is Just the Start - Barron's
- Johnson & Johnson CFO Says Guidance Hike Is Just the Start Barron's
- Johnson & Johnson Bumps Up Guidance as Sales Rise WSJ
- Johnson & Johnson Earnings: Steady Growth and Good Near-Term Visibility Morningstar
- No patent protection for Stelara? No problem for J&J as Tremfya fills the void Fierce Pharma
- J&J quarterly earnings beat Wall Street estimates on strength of medicines unit CNBC
Related Markets
All MarketsMarket data may be delayed. Not financial advice.
💡 AI analysis provides alternative perspectives on current events